We are pleased to introduce a new serine protease inhibitor, Camostat mesilate (ISP-3606-PI) for research use.
Currently, camostat mesylate (or mesilate) is clinically approved in Japan as a serine protease type II transmembrane serine protease (TMPRSS2) inhibitor for the treatment of pancreatitis. TMPRSS2 is also required for viral spike protein (S Protein) priming, allowing viruses, such as coronaviruses, to enter into cells. As an inhibitor of TMPRSS2, it subsequently blocks viral lung cell entry. According to researchers in Japan, it was seen to block SARS-CoV-2 entry into human cells.1,2 Additionally, camostat mesilate is helpful in treating cystic fibrosis by blocking prostasin, a serine protease responsible for sodium channel activity, by reducing sodium transport. Prostasin inhibition also plays a useful role in reducing blood pressure and renal damage in sodium-sensitive hypertension.3,4
Please see our new COVID-19 Information Station, that aggregates all of our related material in one place.
Related topics: ACE2, Angiotensin, Angiotensin TrypTides, Bradykinin, Bradykinin TrypTides, Influenza Matrix Protein M1 (58-66), COVID-19, custom antibodies, OVA Peptide (257-264), putative orf1ab polyprotein (3233-3247) [SARS coronavirus]
- M Hoffmann, et al., Cell, 181, 1 (2020).
- C. Liu, et al., ACS Central Science, Article ASAP (2020).
- Ai Maekawa, et al, Journal of Hypertension, 27(1), 181 (2009).
- S. M. Rowe, et al., Chest., 144(1), 200 (2013).